Regarding: “Stent-graft repair of traumatic thoracic aortic disruptions”  by Morishita, Kiyofumi et al.
although there is no literature on the subject. In addition, our rate
of autogenous AVA construction has reached about 70% with the
aid of preoperative mapping and other techniques.5 We therefore
do not perform transpositions at all costs but rather in selected
patients, especially in those with known or suspected hypercoagu-
lability.
Another factor that arises from the use of transposed veins is
that if they occlude, that arm can no longer be used for any kind of
AVA. On the other hand, at least two prosthetic AVAs can be
constructed in the same arm in case of occlusion.
We suggest that vein transposition can be used to increase the
availability of autogenous veins for AVA but that they should be
used selectively, and if used, then skip incisions might reduce
morbidity and allow earlier initiation of venipuncture.
David Shemesh, MD
Oded Olsha, MB,BS
Shaare Zedek Medical Center
Jerusalem, Israel
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Reply
We thank Shemesh and Olsha for their comments and appre-
ciate the points raised because they further underscore many of the
issues we feel are essential to amplify the use of autogenous veins
for the creation of arteriovenous fistulas. Regarding the use of skip
incisions, we do not think that their use in the dissection of the
brachial vein is a good idea. This vein is very thin and has multiple
small branches, and to free it safely for transposition and prevent
injury, a long incision that provides better exposure is superior.
With regard to flap necrosis from long incisions, as we men-
tioned in our note, care has to be taken not to undermine the
incision. As long as flaps are avoided, the chance of skin necrosis is
minimized. As a matter of fact, we have not seen this complication
in either basilic or brachial vein transposition arteriovenous fistulas.
We agree that one should be selective in choosing the correct
patient for this type of arteriovenous fistula creation. In patients
with small veins, a synthetic arteriovenous graft may be the more
optimal choice. Shemesh and Olsha are to be commended for such
a high secondary patency rates in their arteriovenous grafts. In our
institutions, however, the secondary patency rate has been in the
60% to 70% at 1 year, similar to that reported in the literature. We
believe, therefore, that increasing the prevalence of autogenous
fistula creation, as stated in the guidelines set forth by TheNational
Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-
DOQI) guidelines, should lead to an overall increased arterio-
venous access patency, decreased costs, and decreased morbidity.
The brachial vein is simply another conduit to consider in those
without suitable superficial venous anatomy, such as cephalic or
basilic veins, in the creation of native arteriovenous fistulas.
Hernan A. Bazan, MD
Mount Sinai Hospital
New York, NY
Harry S. Schanzer, MD
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Regarding: “Stent-graft repair of traumatic thoracic
aortic disruptions”
There have been various developments in recent years in the
management of traumatic thoracic aortic disruptions. Endovascu-
lar stent grafting has emerged as an attractive option. Wellons et al
(J Vasc Surg 2004;40:1095-100) experienced 10 patients with
traumatic thoracic aortic disruptions between January 2003 and
March 2004. One patient underwent open repair because of a
short neck. The remaining nine patients received endoluminal
stent-graft repair, with successful exclusion of the traumatic dis-
ruption. One patient died of cerebral injury. No patient had spinal
cord ischemia.
We have treated 21 patients with traumatic thoracic aortic
disruptions during the last 50 months. Ten patients underwent
endovascular stent grafting. One patient died of bilateral lung
injuries. A change to open repair was made 14 days after the initial
stent grafting in a 29-year-old patient because of migration. Fol-
low-up computed tomography scans showed disappearance of
aortic injuries in the remaining patients. No patient developed
paraplegia. The immediate outcomes of endograft repair appear to
be promising.
Wellons et al probably intended to apply this less invasive
treatment to all patients with traumatic thoracic aortic disruptions
during the study period. However, we disagree with their strategy.
We believe that open repair should be performed in young patients
without other serious associated injury, especially cerebral hemor-
rhage, for the following two reasons:
First, the early results for young patients in our series who
underwent surgical intervention were excellent. Without other
serious associated injuries, operative death was zero.
Second, stent-graft migration is a concern. In our patients, the
sizes of prosthetic vascular grafts used in stent grafting were larger
in elderly patients than in young patients. Thus, young patients
may have dilation of the aorta as they get older and may experience
stent migration in the late period. In addition, it is often difficult to
follow up young patients after discharge. We have observed two
graft migrations in 120 patients who had undergone endovascular
stent grafting of the descending thoracic aorta. Both migrations
occurred in young patients.
Considering these facts, durability of stent grafts for young
patients is doubtful. Therefore, open repair should be the first
choice of treatment for traumatic aortic injury in young patients
without serious associated injury.
Traditionally, there were two methods for treating blunt trau-
matic aortic rupture: immediate surgical treatment and delayed
surgical treatment. Endovascular stent grafting has been added to
the conventional treatments. The management of acute aortic
injury should be individualized according to the information from
patients.
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Reply
I appreciate the comments from Morishita, Kurimoto, and
Abe regarding our paper on the repair of traumatic thoracic
disruptions with commercially available stent grafts. Their con-
cerns are justified, and we are certainly not advocating blanket
application of these devices in all patients with thoracic disruptions.
In fact, strong consideration for traditional open repair should be
made in all healthy patients, especially in light of the unknown
long-term consequences of these stent grafts.
We have not had any incidents of stent-graft migration in our
small series, however, and believe that this should not occur when
the device is appropriately oversized. When one considers that the
aorta proximal and distal to the tear is relatively healthy in young
patients with this injury, the graft should be particularly well
fixated. In addition, the disease process should allow for rapid
healing around the implant, leadingmore to concern for long-term
in-stent stenosis than aortic degeneration or stent migration. In
comparison, patients with aneurysmal disease have irregular ath-
erosclerotic diseased vessels that are not particularly suited for
adherence, and thus, stents are prone to migration. Only long-
term data on patients treated with stent grafts will help delineate
the most appropriate candidates.
Stent-graft repair of traumatic thoracic disruptions is a new
treatment for a devastating injury. Our study demonstrated the
feasibility with commercially available devices. The coming United
States Food and Drug Administration approval of a thoracic stent
graft for aneurysmal disease will only increase the use for traumatic
injuries. We agree that treatment strategies should be individual-
ized on the basis of associated injuries and available services but are
more encouraged about the potential benefits of stent grafts in all
patients, even young ones.
Eric Wellons, MD
Atlanta Medical Center
Atlanta, Ga
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